Claritas Completes Acquisition of Exclusive Worldwide Rights to Develop and Commercialize R-107 for Pulmonary Disease

SAN FRANCISCO, CA and TORONTO, ON, Dec. 21, 2021 (GLOBE NEWSWIRE) — Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas“) today announced that it has entered into a License Amendment dated December 17, 2021 (the “License Amendment”) under which Salzman Group, Inc. (a Delaware corporation), Salzman Group, Ltd. (an Israeli corporation), and Salzman Group Pty. Ltd. (an Australian corporation), (collectively, the Salzman Group”), have granted to Claritas an exclusive, worldwide license to develop and commercialize R-107 for the treatment of pulmonary diseases, including pulmonary arterial hypertension (“PAH”) acute respiratory distress syndrome (“ARDS”), and persistent pulmonary hypertension of the newborn (“PPHN”). The Company has received all regulatory approvals for the License Amendment, including approval of the TSX Venture Exchange. Read More